Author: OurCrowd

[CoreMap in GlobeNewswire] CoreMap, Inc. Receives U.S. FDA Investigational Device Exemption (IDE) Approval for INvENI Map-Guided AF Ablation Study

BURLINGTON, Mass., May 28, 2025 (GLOBE NEWSWIRE) — CoreMap today announced it has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to extend the INvENI clinical study into the U.S. This study is designed to evaluate the safety and effectiveness of the proprietary CoreMap™ Endocardial Electrophysiology (EP) Mapping System in patients with persistent Atrial Fibrillation (AF) and long-standing persistent AF. To date, CoreMap has demonstrated safety and acute effectiveness of its EP Mapping system in over 50 patients. Read...

Read More

[Recogni in PR Newswire] Recogni and DataVolt Partner to Deliver the World’s Most Energy-Efficient AI Cloud Infrastructure

SAN JOSE, Calif. and RIYADH, Saudi Arabia, May 28, 2025 /PRNewswire/ — Recogni Inc., the Generative AI Inference systems company, and DataVolt, the sustainable AI-cloud innovator, are teaming up to build the most energy-efficient AI cloud on the planet. Recogni and DataVolt share a commitment to delivering high-performance, energy-efficient AI cloud solutions at scale. This partnership presents a unique opportunity to drive innovation in next-generation AI cloud compute, while advancing environmentally sustainable infrastructure.  Read more...

Read More